Analysts Set Amgen Inc. (NASDAQ:AMGN) Price Target at $380.43

Amgen Inc. (NASDAQ:AMGN) has earned a consensus rating of “Hold” from the thirty research firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $380.4286.

A number of equities analysts recently weighed in on the company. The Goldman Sachs Group set a $389.00 price objective on Amgen in a report on Friday, June 5th. Daiwa Securities Group cut their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. UBS Group increased their target price on shares of Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Robert W. Baird lifted their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Finally, Truist Financial increased their target price on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Range Advisory LLC boosted its position in Amgen by 38.8% during the 2nd quarter. Range Advisory LLC now owns 1,680 shares of the medical research company’s stock valued at $608,000 after acquiring an additional 470 shares in the last quarter. Brown Lisle Cummings Inc. raised its holdings in Amgen by 0.3% in the second quarter. Brown Lisle Cummings Inc. now owns 24,121 shares of the medical research company’s stock worth $8,735,000 after purchasing an additional 80 shares in the last quarter. Cornerstone Financial Management LLC lifted its position in Amgen by 7.2% during the second quarter. Cornerstone Financial Management LLC now owns 459 shares of the medical research company’s stock valued at $166,000 after buying an additional 31 shares during the period. HORAN Wealth LLC boosted its holdings in shares of Amgen by 1.9% during the 2nd quarter. HORAN Wealth LLC now owns 15,478 shares of the medical research company’s stock valued at $5,605,000 after buying an additional 284 shares in the last quarter. Finally, Amundi boosted its stake in Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock worth $1,408,715,000 after acquiring an additional 512,883 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

NASDAQ:AMGN opened at $442.84 on Friday. The stock has a market cap of $239.41 billion, a P/E ratio of 27.52, a PEG ratio of 3.16 and a beta of 0.43. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The business’s 50-day moving average price is $393.99 and its two-hundred day moving average price is $366.13. Amgen has a twelve month low of $269.77 and a twelve month high of $447.03.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period last year, the firm posted $6.02 earnings per share. Amgen’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts predict that Amgen will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s payout ratio is presently 62.65%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New evidence that Amgen’s cholesterol drug Repatha reduced the risk of death among patients at high risk of heart attack or stroke strengthens the drug’s clinical profile and could support broader use, sales growth and reimbursement. Amgen’s Repatha reduces risk of death in people at high risk of heart attack or stroke
• Positive Sentiment: Commentary highlighted Repatha’s potentially significant cardiovascular opportunity, adding to investor enthusiasm about a product that could become an important long-term growth driver beyond Amgen’s current results. Jim Cramer on Amgen’s cardiovascular opportunity
• Positive Sentiment: Analyst H. Engel of Erste Group raised the firm’s 2027 EPS estimate to $24.43 from $23.50, signaling improved expectations for Amgen’s earnings trajectory, although the firm maintained a Hold rating.
• Neutral Sentiment: Amgen will present at the Wells Fargo Healthcare Conference, giving investors a potential update on its pipeline, commercial outlook and strategy. The announcement itself contains no new financial guidance. Amgen to present at the 2026 Wells Fargo Healthcare Conference
• Negative Sentiment: U.K. regulators suspended Tavneos for new patients and halted its sale after determining that the main supporting study contained unreliable data. The action threatens sales of the rare-disease treatment and raises the risk of additional regulatory scrutiny or restrictions in other markets. UK regulator suspends Amgen’s Tavneos for new patients

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.